Benjamin P. Saylor

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.

The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.

Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.

According to the company, the MHRA approval represents the first marketing approval outside the US for NAI.

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

Here’s a look back at notable news between April and June 2025.

A comprehensive guide to the key regulatory decisions and conferences slated for Q3 of 2025.

The approach was associated with a 30% decrease in PSMA uptake by the salivary glands without compromising the treatment’s efficacy.

ORR in the zanzalintinib plus nivolumab arm was 63% (95% CI: 46-77) vs 40% (95% CI: 25-57) in the zanzalintinib plus nivolumab/relatlimab arm.

In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.

Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo

“This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.

Clinical benefit rate was observed 5 (27%) patients in cohort 1, 7 (27%) patients in cohort 2, and 2 (11%) patients in cohort 3.

“As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.

“Prior taxanes did not increase reported hematological adverse events during treatment with Ra-223,” the investigators reported.

Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.

“On the intention-to-treat efficacy analysis...the median PFS was numerically higher for the paclitaxel arm," said Aditya Dhanawat, MBBS, MD, DM.

The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.

"The pre-specified thresholds for statistical significance were not met for the dual primary end points of overall survival in cisplatin-ineligible and PD-L1 positive patients," said Michiel Van der Heijden, MD, PhD.

"There was activity across all the groups from an EFS perspective," said Thomas B. Powles, MBBS, MRCP, MD.

Vitaly Margulis, MD, reported an overall response rate of 86.5%, and a complete response rate of 73%.

The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.

"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD.

“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.

"The black box warning affects that ability for them to get access to that critical drug, vaginal estrogen," says Yahir A. Santiago-Lastra, MD.

Among the guideline’s recommendations is the use of local low-dose vaginal estrogen as first-line therapy for GSM.

The study was published in JCO Oncology Practice.

John Michael DiBianco, MD, discusses findings from the BLUES trial.